PRECISELY Targeted Therapies for patients with cancer
With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer.
We design innovative small molecules that precisely inhibit clinically proven kinase targets to solve for the dual challenges of resistance and selectivity.
We partner with physician-scientists to identify patient needs and the limitations of existing therapies.
We are passionate about using our expertise to address the needs of patients with cancer.
Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation SummitRead More >
Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial ResultsRead More >
Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology DaysRead More >
Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023Read More >